{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:36Z","timestamp":1790236656712,"version":"4.1.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.2169\/internalmedicine.4526-24","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:11:43Z","timestamp":1738948303000},"page":"2494-2499","source":"Crossref","is-referenced-by-count":1,"title":["Concurrent Therapy for Immunoglobulin Light Chain Cardiac Amyloidosis and Transthyretin Cardiac Amyloidosis"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuichi","family":"Horigome","sequence":"first","affiliation":[{"name":"Department of Hematology, Kitasato University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinta","family":"Hatakeyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitasato University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129: 2111-2119, 2017.","DOI":"10.1182\/blood-2016-11-751628"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Muchtar E, Gertz MA, Lacy MQ, et al. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol 187: 588-594, 2019.","DOI":"10.1111\/bjh.16096"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Muchtar E, Dispenzieri A, Gertz MA, et al. Treatment of AL amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement 2020 update. Mayo Clin Proc 96: 1546-1577, 2021.","DOI":"10.1016\/j.mayocp.2021.03.012"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133: 2404-2412, 2016.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sidiqi MH, McPhail ED, Theis JD, et al. Two types of amyloidosis presenting in a single patient: a case series. Blood Cancer J 9: 30, 2019.","DOI":"10.1038\/s41408-019-0193-9"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39: 2799-2806, 2018.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68: 1014-1020, 2016.","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30: 989-995, 2012.","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126: 612-615, 2015.","DOI":"10.1182\/blood-2015-01-620302"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 120: 3206-3213, 2012.","DOI":"10.1182\/blood-2012-03-413682"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int 70: 191-198, 2020.","DOI":"10.1111\/pin.12902"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Solomon A, Murphy CL, Westermark P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch Pathol Lab Med 132: 14; author reply 14-15, 2008.","DOI":"10.5858\/2008-132-14a-UOIFTA"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Donnelly JP, Gabrovsek A, Sul L, et al. Evidence of concurrent light chain and transthyretin cardiac amyloidosis in 2 patients. JACC CardioOncol 2: 127-130, 2020.","DOI":"10.1016\/j.jaccao.2020.01.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Geller HI, Singh A, Mirto TM, et al. Prevalence of monoclonal gammopathy in wild-type transthyretin amyloidosis. Mayo Clin Proc 92: 1800-1805, 2017.","DOI":"10.1016\/j.mayocp.2017.09.016"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Phull P, Sanchorawala V, Connors LH, et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 25: 62-67, 2018.","DOI":"10.1080\/13506129.2018.1436048"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2: e000098, 2013.","DOI":"10.1161\/JAHA.113.000098"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362-1369, 2006.","DOI":"10.1056\/NEJMoa054494"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium <sup>99<\/sup>m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1: 880-889, 2016.","DOI":"10.1001\/jamacardio.2016.2839"},{"key":"19","unstructured":"19. Kastritis E, Palladini G, Minnema MC, et al; the ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385: 46-58, 2021."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Maurer MS, Schwartz JH, Gundapaneni B, et al; the ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379: 1007-1016, 2018.","DOI":"10.1056\/NEJMoa1805689"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4526-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T03:43:15Z","timestamp":1755315795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/16\/64_4526-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4526-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"4526-24"}}